Calamos Advisors LLC Buys New Stake in Masimo Co. (NASDAQ:MASI)

Calamos Advisors LLC bought a new stake in Masimo Co. (NASDAQ:MASI) in the 4th quarter, HoldingsChannel reports. The fund bought 16,280 shares of the medical equipment provider’s stock, valued at approximately $2,691,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC lifted its holdings in shares of Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after purchasing an additional 1,970,883 shares during the last quarter. State Street Corp increased its position in Masimo by 0.7% during the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock valued at $191,837,000 after buying an additional 10,179 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after buying an additional 262,370 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after acquiring an additional 11,984 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Masimo by 9.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider’s stock worth $105,619,000 after acquiring an additional 70,440 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Stock Up 2.1 %

MASI stock opened at $175.70 on Wednesday. The company has a market capitalization of $9.41 billion, a P/E ratio of 121.17 and a beta of 1.02. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $183.14. The firm’s fifty day simple moving average is $171.24 and its 200-day simple moving average is $145.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 earnings per share. As a group, equities research analysts forecast that Masimo Co. will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on MASI. BTIG Research increased their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Piper Sandler raised their price target on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Raymond James upped their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Finally, Wells Fargo & Company raised their target price on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.40.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.